TGFB1 and Hepatic fibrosis: Co-administration of total astragalosides (AST) and glycyrrhizic acid (GA) markedly inhibits HSC activation, lowers α-SMA and COL1A1 expression, and suppresses transcription and phosphorylation of TGF-β1 and Smad2/3, thereby reversing dimethylnitrosamine (DMN)– or bile duct ligation (BDL)–induced hepatic fibrosis (Zhou et al., 2016).